Circulating Tumor DNA Reveals Mechanisms of Lorlatinib Resistance in Patients With Relapsed/Refractory ALK-Driven Neuroblastoma

Scientists established the clinical utility of serial circulating tumor DNA sampling to track response and progression and discover acquired resistance mechanisms that can be leveraged to develop therapeutic strategies to overcome lorlatinib resistance.